证券代码：300003 证券简称：乐普医疗 公告编号：2023-052 乐普（北京）医疗器械股份有限公司 第六届监事会第三次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 乐普（北京）医疗器械股份有限公司（以下简称"乐普医疗"或"公司"） 第六届监事会第三次会议于 2023 年 8 月 25 日在北京市昌平区超前路 37 号公 司会议室以现场及通讯相结合的方式召开，会议通知于 2023 年 8 月 20 日以邮 件方式送达。会议应出席监事 3 名，实际出席监事 3 名。本次会议召开符合《公 司法》及《公司章程》的相关规定。会议由监事会主席王兴林先生主持，出席会 议的监事审议并通过记名投票方式表决通过了如下决议： 一、审议《关于公司 2023 年半年度报告及报告摘要》的议案 三、审议《关于使用部分闲置募集资金暂时补充流动资金》的议案 经审核，监事会认为董事会编制和审核的公司 2023 年半年度报告及报告摘 要的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整 地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或重大遗漏。 同意 3 ...

证券代码：300003 证券简称：乐普医疗 公告编号：2023-058 乐普（北京）医疗器械股份有限公司 关于公司向银行延续申请授信额度的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 乐普（北京）医疗器械股份有限公司（以下简称"公司"）于 2023 年 8 月 25 日召开公司第六届董事会第三次会议，审议通过《关于公司向银行延续申请 授信额度》的议案。为满足公司生产经营及业务拓展的需要，公司拟向以下银行 延续申请授信额度，具体情况预计如下： | 序号 | 银行 | 授信额度 | | --- | --- | --- | | 1 | 工商银行 | 不超过 8 亿元 | | 2 | 兴业银行 | 不超过 20 亿元 | | 3 | 北京银行 | 不超过 5 亿元 | | 4 | 中信银行 | 不超过 5 亿元 | | 5 | 民生银行 | 不超过 10 亿元 | 最终授信额度将以实际审批的授信额度为准，具体融资金额将视公司经营实 际需求确定。 本次向合作银行申请综合授信额度自董事会决议生效之日起有效期三年（有 效期内可多次审批，额度循环使用），公司董事会授权董事长 ...

证券代码：300003 证券简称：乐普医疗 乐普（北京）医疗器械股份有限公司 投资者关系活动记录表 编号：2023-01 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 ■业绩说明会 | | | □新闻发布会 □路演活动 | | 类别 | □现场参观 | | | □其他 | | 参与单位名称及 | | | | 261 家境内外机构共 379 名参会人员，详见附件明细 | | 人员姓名 | | | 时间 | 年 月 日 2023 4 26 | | 地点 | 电话会议 | | 上市公司接待人 | 董事长 蒲忠杰 | | | 财务总监 王泳 | | 员姓名 | 董事会秘书 江维娜 | | | 蒲总：感谢新老朋友们参会，大家晚上好！今天我主要从 | | | 以下五方面给大家汇报：第一，经营数据回顾；第二，创新与 | | | 发展公司做出的努力；第三，公司新增长极消费医疗正在崛起； | | | 四，慢病领域人工智能应用；第五，国际化战略与途径。 | | | （1） 经营数据：在政策扰动和疫情管控大环境下， | | 投资者关系活动 | 2021、2022 年这两年 ...

Financial Performance - The company reported significant financial metrics in the annual report, including total revenue and net profit figures, which are crucial for assessing performance [7]. - The company's operating revenue for 2022 was ¥10,609,442,080.61, a decrease of 0.47% compared to 2021 [12]. - Net profit attributable to shareholders for 2022 was ¥2,202,809,390.54, an increase of 28.12% year-over-year [12]. - The net profit after deducting non-recurring gains and losses was ¥2,142,486,458.55, reflecting a 15.50% increase from the previous year [12]. - The total assets at the end of 2022 amounted to ¥24,484,033,145.01, representing an 18.29% increase from the end of 2021 [12]. - The company's basic earnings per share for 2022 was ¥1.2223, up 27.38% from ¥0.9596 in 2021 [12]. - The cash flow from operating activities for 2022 was ¥2,790,709,307.02, a decrease of 8.86% compared to 2021 [12]. - The weighted average return on equity for 2022 was 17.60%, an increase of 1.60% from 16.00% in 2021 [12]. Market Strategy and Expansion - The company is focused on expanding its market presence and developing new products and technologies to enhance its competitive edge [4]. - The company has a strategic plan for mergers and acquisitions to bolster its growth and market share in the medical device sector [4]. - The company plans to continue leveraging its competitive advantages in R&D, cost control, and supply management to enhance market share amid ongoing procurement reforms [25]. - The company aims to expand its market share in cardiovascular intervention by leveraging its competitive advantages and responding proactively to volume-based procurement policies [30]. - The company has established a presence in over 150 countries and regions, with a focus on increasing overseas sales and brand recognition through participation in global medical device exhibitions [32]. - The company raised USD 220 million through GDR listing on the Swiss Six Swiss Exchange, which will support its international expansion efforts [32]. - The company is exploring vertical segments in ophthalmology, dentistry, and dermatology through a combination of self-incubation and acquisitions, marking 2023 as the year for consumer healthcare growth [31]. Research and Development - The company is actively investing in research and development to innovate and improve its product offerings [4]. - The company has filed a total of 1,650 patents and has over 600 products listed domestically and internationally as of December 31, 2022 [26]. - The company has received 569 NMPA approvals for Class II and III medical devices, 33 FDA certifications, and 224 CE certifications [26]. - The company plans to launch several key innovative products from 2023 to 2026, including a blood flow reserve measurement device and a drug-coated balloon, enhancing its product pipeline in cardiovascular intervention [31]. - The company is focusing on innovative solutions to meet clinical needs, such as the self-expanding ScienCrown® valve, which offers significant advantages over existing products [40]. - The company is developing a new generation of non-invasive blood glucose monitoring devices, with clinical trials nearing completion and meeting registration standards for sensitivity and accuracy [73]. - The company is actively exploring AI applications in personalized treatment recommendations for chronic disease patients, particularly in diabetes and hypertension [73]. Governance and Compliance - The company’s governance structure and compliance with regulatory requirements were outlined, ensuring accountability and integrity in operations [4]. - The company is committed to maintaining transparency and accuracy in its financial reporting, as stated by its management team [2]. - The company has established a performance evaluation and incentive system linking executive compensation to business performance, promoting transparency [161]. - The company strictly adheres to governance regulations, ensuring independent operation and management separate from its controlling shareholders [157]. - The company maintains independence from its controlling shareholders in terms of business operations, personnel, and financial management [166]. Risk Management - The management discussion highlighted potential risks that the company may face in the future, which is essential for investors to consider [2]. - The company faces risks from bulk procurement policies affecting medical consumables and generic drugs, which may lead to price reductions [147]. - The company is committed to diversifying its product portfolio to mitigate the impact of bulk procurement on revenue and profit [147]. - The company is enhancing its R&D capabilities to address risks associated with product development and regulatory approvals [148]. Investor Relations - The company held multiple investor communication events, with 243 participants in the half-year meeting and 378 in the third-quarter meeting, indicating strong investor interest [154]. - The company actively manages investor relations through various channels, enhancing communication and interaction with investors [163]. Employee Development - The company has established a comprehensive training system for employee development [195]. - The total number of employees at the end of the reporting period is 10,652, with 2,115 in the parent company and 8,537 in major subsidiaries [193]. - The professional composition includes 3,622 production personnel, 3,409 sales personnel, 2,663 technical personnel, 278 financial personnel, and 680 administrative personnel [193]. Profit Distribution - The company proposed a profit distribution plan, distributing a cash dividend of 3.41 CNY (including tax) for every 10 shares, with no bonus shares issued [3]. - The total cash dividend distributed was 880,967,306.55 yuan, which represents 100% of the distributable profit [199]. - The company has a cash dividend policy that requires a minimum of 20% of profits to be distributed as cash dividends during growth phases [199]. - The profit distribution plan complies with the company's articles of association and relevant regulations [197].

Financial Performance - The company's revenue for Q1 2023 was CNY 2,437,202,386.92, a decrease of 4.39% compared to CNY 2,549,111,243.52 in the same period last year[4] - Net profit attributable to shareholders increased by 9.45% to CNY 596,924,222.49, up from CNY 545,393,656.31 year-on-year[4] - The net profit for the first quarter of 2023 was CNY 618.32 million, an increase of 10% compared to CNY 562.13 million in the same period last year[21] - The total comprehensive income attributable to the parent company was CNY 638.69 million, up from CNY 419.81 million year-on-year[22] - Basic earnings per share increased to CNY 0.3205 from CNY 0.3054 in the previous year, reflecting a growth of approximately 6.8%[22] - Operating profit for the quarter was CNY 699.84 million, slightly up from CNY 684.52 million in the same quarter of the previous year[21] Cash Flow and Liquidity - The net cash flow from operating activities showed a significant decline, with a net outflow of CNY 134,203,435.01, a decrease of 129.89% compared to a net inflow of CNY 448,932,891.19 in the previous year[4] - Cash and cash equivalents at the end of the period were CNY 5,297,999,204.12, a decrease of 3.1% from CNY 5,467,278,785.39 at the beginning of the year[18] - Cash and cash equivalents at the end of the period were CNY 5.17 billion, down from CNY 3.53 billion at the end of the previous year[24] - Investment activities resulted in a net cash outflow of CNY 212.41 million, an improvement from a net outflow of CNY 436.73 million in the same period last year[24] - The company experienced a foreign exchange loss of CNY 42.62 million, impacting the overall cash position[24] Assets and Liabilities - The company’s total assets at the end of the reporting period were CNY 24,559,902,516.86, reflecting a slight increase of 0.31% from the previous year[4] - Total liabilities decreased to CNY 7,477,548,984.26, down from CNY 8,113,549,880.82 at the beginning of the year[19] - The company's equity attributable to shareholders increased to CNY 15,823,636,468.24, compared to CNY 15,146,202,761.30 at the beginning of the year[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 83,934, with the top ten shareholders holding a combined 60.94% of shares[12] - The largest shareholder, China Shipbuilding Industry Group Company, holds 12.98% of shares, totaling 244,063,788 shares[12] - WP Medical Technologies, Inc. is the second-largest shareholder with 12.13%, holding 228,074,749 shares[12] - The top ten shareholders include various investment funds and individuals, with the largest being state-owned entities and private investors[12] - The company has a significant portion of shares pledged, with 171,056,062 shares pledged by shareholder Pu Zhongjie[14] Operational Highlights - The cardiovascular intervention product line achieved positive growth despite a general decline in sales, with the medical services and health management segment growing by 16.06% year-on-year[8] - Research and development expenses increased to CNY 229,686,257.30, up 8.1% from CNY 212,393,810.51 in the previous year[20] - Total operating costs decreased to CNY 1,749,019,988.44, down 5% from CNY 1,840,886,155.20 year-over-year[20] - Gross profit margin improved to approximately 28.3%, compared to 26.5% in the previous year[20] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[20]

关于举行 2022 年度和 2023 年一季度网上业绩说明会公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 证券代码：300003 证券简称：乐普医疗 公告编号：2023-029 乐普（北京）医疗器械股份有限公司 特此公告。 乐普（北京）医疗器械股份有限公司 董事会 二○二三年四月二十五日 乐普（北京）医疗器械股份有限公司（以下简称：公司）《2022 年年度报 告》和《2023 年一季度报告》于 2023 年 4 月 26 日刊登于中国证监会创业板指 定的信息披露网站。为便于投资者进一步了解公司的生产经营情况，公司将于 2023 年 5 月 12 日（星期五）下午 15:00-17:00，以网络远程互动方式召开 2022 年度和 2023 年一季度网上业绩说明会。投资者可登陆全景网"投资者关系互动 平台"（https://ir.p5w.net）参与本次业绩说明会。 出席本次业绩说明会的人员有：公司董事长蒲忠杰先生，独立董事曲新女士， 董事会秘书江维娜女士，高级副总经理兼财务总监王泳女士，保荐代表人刘君女 士。 欢迎广大投资者积极参与！ ...